
Esperion Therapeutics (ESPR) Stock Forecast & Price Target
Esperion Therapeutics (ESPR) Analyst Ratings
Bulls say
Esperion Therapeutics has demonstrated significant financial momentum, highlighted by a 53% increase in product revenue to $31.1 million for the quarter, driven by remarkable retail prescription growth of 12% from the previous quarter and 44% compared to the same quarter last year. The company benefits from increased prescription growth in Europe, with Daiichi Sankyo Europe's efforts contributing to a 19% sequential rise in royalty revenues to $8.9 million based on NILEMDO and NUSTENDI sales, reflecting a robust market presence. Furthermore, improvements in preferred commercial and Medicare coverage exceeding 92% and 65%, respectively, indicate strong confidence from healthcare providers, suggesting positive sales expectations for the future.
Bears say
Esperion Therapeutics Inc. faces a challenging financial outlook due to a history of consistent losses and the absence of a track record for profitability. Recent reports indicate that the company has lowered its sales estimates for the current year, reflecting growing concerns over demand for its products amid potential competitive threats. Additionally, the risk of breakthrough therapies rendering Esperion's offerings obsolete adds further uncertainty, thereby impacting the company's long-term viability and market position.
This aggregate rating is based on analysts' research of Esperion Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Esperion Therapeutics (ESPR) Analyst Forecast & Price Prediction
Start investing in Esperion Therapeutics (ESPR)
Order type
Buy in
Order amount
Est. shares
0 shares